Poellmann LJ et al., 2026: Retrospective multicentre case series of six dogs that developed severe febrile cytopenia after fenbendazole treatment for Heterobilharzia americana. All recovered after the drug was stopped and supportive care given.
Dogs developed marked neutropenia, variable thrombocytopenia, fever, and severe clinical illness warranting hospitalization.
Poellmann LJ et al., 2026: Retrospective multicentre case series of six dogs that developed severe febrile cytopenia after fenbendazole treatment for Heterobilharzia americana. All recovered after the drug was stopped and supportive care given. Observational retrospective multicentre case series; N=6 client-owned dogs, all spayed females; United States (Texas A&M Gastrointestinal Laboratory); fenbendazole dose not stated per dog, but five of six also received a praziquantel/pyrantel/febantel combination tablet, giving high total benzimidazole exposure; cases accrued June 2023-November 2025. Funder: not stated. Declared conflicts: none recorded in the PubMed record. Product: fenbendazole products, manufacturers not named in the abstract. Comparator: none. Confounded by concurrent benzimidazole exposure in 5 of 6 dogs, which the authors themselves flag. Study type: uncontrolled series.
